Company Profile
Beyond Air Stock Price, News & Analysis
- Ticker:
- XAIR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.56 USD (-2.28%)
Close
Last updated: August 6, 2026
5.97M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, XAIR closed down 2.28% at $5.56. No new same-company headline was identified in the current news window.
Company overview
Nitric Oxide Medical Technology Platform
Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors. Its first product, LungFit PH, is FDA-approved and CE-marked for hypoxic respiratory failure in term and near-term newborns.
Cylinder-Free LungFit System
LungFit is a phasic-flow nitric oxide generation and delivery system that produces nitric oxide from ambient air without high-pressure cylinders. The design reduces cylinder inventory, storage requirements, and nitrogen dioxide venting while simplifying hospital operations.
Commercial and International Reach
Beyond Air is commercializing LungFit PH in the United States and through a distribution network covering more than 45 countries. Regional partners provide regulatory and market access beyond the company’s direct U.S. organization.
Second-Generation Product Strategy
The second-generation LungFit PH is designed to be smaller, lighter, easier to operate, and suitable for a broader range of care settings. The updated system is also intended to support patient transport use.
Nitric Oxide Platform Beyond Respiratory Care
Beyond Air is also exploring nitric oxide biology in neurological disease and solid tumors. These programs extend the company’s technology base beyond hospital respiratory delivery, although LungFit PH remains its commercial foundation.
Future catalysts
An FDA decision is pending on the PMA supplement for the second-generation LungFit PH system.
The PMA supplement also seeks an expanded label covering use during air and ground patient transport.
Regional regulatory submissions for LungFit PH continue through local partners, with future approvals determining the scope of international commercialization.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Beyond Air (XAIR)?
Beyond Air (XAIR) most recently closed at 5.56 USD, a -2.28% move versus the previous session.
What is the market cap of Beyond Air (XAIR)?
Beyond Air currently has a market capitalization of 5.97M USD on BioPharmSignal.
What does Beyond Air do?
Nitric Oxide Medical Technology Platform Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors. Its first product, LungFit PH, is FDA-approved and CE-marked for hypoxic respiratory failure in term and near-term...
On which exchange is XAIR stock listed?
Beyond Air (XAIR) is associated with NASDAQ, United States, Biopharma.
What is Nitric?
Nitric Oxide Medical Technology Platform Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors.
Which conditions is Beyond Air targeting with Nitric?
Beyond Air is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Beyond Air describe recent progress with Nitric?
An FDA decision is pending on the PMA supplement for the second-generation LungFit PH system. The PMA supplement also seeks an expanded label covering use during air and ground patient transport. Regional regulatory submissions for LungFit PH continue through local partners, with future approvals determining the scope of international commercialization.
What is Oxide?
Nitric Oxide Medical Technology Platform Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors.